(Q36790161)

16 August 2017

1 reference

title

New developments in the treatment of gastrointestinal neuroendocrine tumors (English)

1 reference

16 August 2017

Matthew H Kulke

1

1 reference

16 August 2017

publication date

1 May 2007

1 reference

16 August 2017

published in

Current Oncology Reports

1 reference

16 August 2017

volume

9

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

177-183

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-007-0019-y

16 August 2017

exact match

0 references

cites work

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

1 reference

12 December 2020

Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in gastrointestinal carcinoids

1 reference

12 December 2020

Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

1 reference

12 December 2020

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate

1 reference

12 December 2020

Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience

1 reference

12 December 2020

High-dose indium 111In pentetreotide radiotherapy for metastatic atypical carcinoid tumor

1 reference

12 December 2020

Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors

1 reference

12 December 2020

Laparoscopic radiofrequency ablation of neuroendocrine liver metastases

1 reference

12 December 2020

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings

1 reference

12 December 2020

Liver transplant for metastatic neuroendocrine tumor

1 reference

12 December 2020

Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin--alone or in combination with 5-FU.

1 reference

12 December 2020

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa

1 reference

12 December 2020

Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumor cell growth

1 reference

12 December 2020

The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours

1 reference

12 December 2020

Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell Carcinoma

1 reference

12 December 2020

Thalidomide is an inhibitor of angiogenesis

1 reference

12 December 2020

Experience with indium-111 and yttrium-90-labeled somatostatin analogs

1 reference

12 December 2020

90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies

1 reference

12 December 2020

Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report.

1 reference

12 December 2020

Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested?

1 reference

12 December 2020

Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome

1 reference

12 December 2020

Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.

1 reference

12 December 2020

Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor

1 reference

12 December 2020

Chemotherapy and biotherapy in the treatment of neuroendocrine tumours

1 reference

12 December 2020

Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies

1 reference

12 December 2020

Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors

1 reference

12 December 2020

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate

1 reference

12 December 2020

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

1 reference

12 December 2020

The Role of Interferons in the Management of Carcinoid Tumors

1 reference

12 December 2020

Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282.

1 reference

12 December 2020

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors

1 reference

12 December 2020

Treatment of the carcinoid tumor and the malignant carcinoid syndrome

1 reference

12 December 2020

Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation

1 reference

12 December 2020

Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway

1 reference

12 December 2020

Yttrium-90 DOTATOC: first clinical results

1 reference

12 December 2020

Embolization and chemoembolization therapy for neuroendocrine tumors

1 reference

12 December 2020

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine

1 reference

12 December 2020

Liver transplantation for metastatic neuroendocrine tumors

1 reference

12 December 2020

Hepatic resection for metastatic neuroendocrine carcinomas

1 reference

12 December 2020

Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon

1 reference

12 December 2020

Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system

1 reference

12 December 2020

Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue

1 reference

12 December 2020

In situ radiotherapy with 111In-pentetreotide: initial observations and future directions.

1 reference

12 December 2020

Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study

1 reference

12 December 2020

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

1 reference

12 December 2020

Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome

1 reference

12 December 2020

Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system

1 reference

12 December 2020

Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors

1 reference

12 December 2020

Expression of vascular endothelial growth factor in digestive neuroendocrine tumours

1 reference

12 December 2020

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

1 reference

12 December 2020

10.1007/S11912-007-0019-Y

Identifiers

DOI

1 reference

release_gnryzgfxcfgh3hvv23t3ldtnuu

16 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gnryzgfxcfgh3hvv23t3ldtnuu

24 November 2022

mapped directly with Wikidata item

1 reference